Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | Real-world safety and efficacy of belantamab mafodotin in R/R myeloma

Malin Hultcrantz • 28 Sep 2023
IMS 2023
Multiple Myeloma Antibodies Belantamab mafodotin
DREAMM-2

Malin Hultcrantz, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the real-world safety and efficacy of belantamab mafodotin in relapsed/refractory multiple myeloma (R/R MM). Despite rates of real-world ocular toxicity being similar to the Phase II DREAMM-2 trial (NCT03525678), patients continued taking belantamab mafodotin. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

GSK Abbvie Amgen BMS

More from Malin Hultcrantz

0:32
The role of immunotherapy in smoldering myeloma
Malin Hultcrantz • 10 Dec 2023
0:53
Should patients with smoldering myeloma be treated outside of the clinical trial setting?
Malin Hultcrantz • 10 Dec 2023
2:26
Serum biomarkers as predictors of disease progression in smoldering myeloma
Malin Hultcrantz • 10 Dec 2023
2:07
Changes in M-spike and FLC and the risk of progression in SMM
Malin Hultcrantz • 28 Sep 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals